Panitumumab: Clinical Trials

178 trials of Panitumumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

99 completed, 27 terminated, 22 unknown, 13 recruiting. 178 Phase 2, 21 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2178Completed 99, Terminated 27, Unknown 22, Recruiting 13, Withdrawn 9, Active not recruiting 7, Suspended 1
Phase 121Completed 14, Recruiting 3, Terminated 3, Unknown 1
Phase 31Unknown 1

Follow Panitumumab: new trials by email Literature Review of Panitumumab trials Research Report on Panitumumab

Trials (filtered) newest first · largest first

All 178 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
VS-7375, cetuximab, panitumumab - Colorectal Cancer
Phase 2RecruitingVerastem, Inc.1502026-07-282026-11-19
89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC
89Zr-panitumumab IV, Panitumumab - Head-and-neck Squamous Cell Carcinoma
Phase 2WithdrawnAndrei Iagaru2026-06-012026-08-17
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Sotorasib, Panitumumab - Advanced Solid Tumors
Phase 2RecruitingAmgen142026-01-022026-11-20
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Telisotuzumab Adizutecan, Fluorouracil, Oxaliplatin - Metastatic Colorectal Cancer
Phase 2RecruitingAbbVie3902025-04-242026-10-27
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
Lonsurf, Oxaliplatin, Panitumumab - Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma
Phase 2RecruitingUNICANCER732025-03-212025-12-10
ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer
irinotecan, panitumumab, Valproic Acid (VPA) - Colorectal Cancer Metastatic
Phase 2RecruitingNational Cancer Institute, Naples1302025-03-122025-12-17
A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer
mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy - Neoplasms
Phase 2RecruitingBlokhin's Russian Cancer Research Center642025-03-012025-05-18
Botensilimab and Balstilimab Optimization in Colorectal Cancer
Botensilimab, Balstilimab, Oxaliplatin - Colorectal Cancer
Phase 2Active not recruitingNicholas DeVito, MD162024-11-182026-02-05
Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study
FOLFOXIRI Protocol - Neoplasm Malignant, Colon Cancer Stage 4
Phase 2UnknownAl-Azhar University602024-08-172024-08-28
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)1052024-08-012026-10-22
Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients
166Holmium TARE, Cetuximab, Panitumumab - Colorectal Cancer Metastatic
Phase 2TerminatedGruppo Oncologico del Nord-Ovest42024-03-132026-01-05
A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab
Oral sotorasib + IV Panitumumab - Efficacy
Phase 2UnknownKorea University Anam Hospital242023-07-032023-08-15
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Trastuzumab deruxtecan, Durvalumab, Panitumumab - Colorectal Cancer, Resectable Colorectal Carcinoma
Phase 2RecruitingGruppo Oncologico del Nord-Ovest1972023-05-112026-09-11
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
S241656, FOLFOX6/FOLFOX7, FOLFIRI - Non-small Cell Lung Cancer, Histiocytic Neoplasm
Phase 1 / Phase 2RecruitingInstitut de Recherches Internationales Servier6232023-04-182026-11-17
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
Phase 2RecruitingNational Cancer Institute (NCI)29002023-04-072026-11-18
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
Sodium Valproate, Panitumumab, Cetuximab - Metastatic Colorectal Cancer
Phase 2Active not recruitingAustralasian Gastro-Intestinal Trials Group382023-01-232026-05-08
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab - Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer
Phase 2TerminatedNorthwestern University72022-10-102026-06-12
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
Carboplatin, Cyclophosphamide, Doxorubicin - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Phase 2WithdrawnM.D. Anderson Cancer Center2022-03-112024-10-24
CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab
CEND-1, Panitumumab, Folfirinox - Colon Cancer, Pancreas Cancer
Phase 1 / Phase 2UnknownAnup Kasi502021-10-202024-12-17
PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence
Regorafenib, Panitumumab - Colorectal Cancer
Phase 2CompletedGruppo Oncologico del Nord-Ovest2132020-12-152026-08-28

Showing 20 of 178. Sign in to see all of them.

Conditions studied

Colorectal Neoplasms (84)  ·  Colonic Neoplasms (22)  ·  Rectal Neoplasms (21)  ·  Neoplasm Metastasis (20)  ·  Neoplasms (14)  ·  Carcinoma, Non-Small-Cell Lung (9)  ·  Esophageal Neoplasms (8)  ·  Cholangiocarcinoma (7)  ·  Breast Neoplasms (6)  ·  Carcinoma, Squamous Cell (6)  ·  Head and Neck Neoplasms (6)  ·  Lung Neoplasms (6)  ·  Pancreatic Neoplasms (6)  ·  Adenocarcinoma Of Esophagus (4)  ·  Carcinoma (4)

Sponsors

Amgen (24)  ·  M.D. Anderson Cancer Center (6)  ·  Vejle Hospital (6)  ·  Grupo Espanol Multidisciplinario del Cancer Digestivo (5)  ·  Gruppo Oncologico del Nord-Ovest (5)  ·  AIO-Studien-gGmbH (4)  ·  Memorial Sloan Kettering Cancer Center (4)  ·  UNICANCER (4)  ·  WiSP Wissenschaftlicher Service Pharma GmbH (4)  ·  Alliance for Clinical Trials in Oncology (3)  ·  Federation Francophone de Cancerologie Digestive (3)  ·  National Cancer Institute (NCI) (3)  ·  National Cancer Institute, Naples (3)  ·  SCRI Development Innovations, LLC (3)  ·  Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) (3)

Countries

United States (73)  ·  Italy (19)  ·  Spain (19)  ·  France (18)  ·  Germany (15)  ·  Belgium (9)  ·  Netherlands (8)  ·  Denmark (7)  ·  Australia (6)  ·  Austria (6)  ·  Canada (6)  ·  Japan (6)  ·  United Kingdom (5)  ·  Greece (4)  ·  Switzerland (4)

Top investigators

Anders Jakobsen, DMSc (2)  ·  Anders Jakobsen, MD, DMSc (2)  ·  Antonio Arrivi, MD (2)  ·  Aram Hezel, MD (2)  ·  Jaime Feliu, MD (2)  ·  Joan Maurel, MD (2)  ·  Jorge Aparicio, MD (2)  ·  Nancy Kemeny, MD (2)  ·  Ruth Vera, MD (2)  ·  Vicente Alonso, MD (2)

Results publications

PMID 18316791, PMID 22070868, PMID 26049686, PMID 34213592, PMID 38592721, PMID 10744089, PMID 10918161, PMID 11247898, PMID 15175435, PMID 15210739, PMID 15870084, PMID 16943526, PMID 17470860, PMID 17671985, PMID 17785764, PMID 18407737, PMID 18506163, PMID 19097774, PMID 19287023, PMID 19339720, PMID 19755046, PMID 21090969, PMID 22000810, PMID 22210091, PMID 22367707, PMID 23041588, PMID 23139259, PMID 23359181, PMID 24138831, PMID 24146220, PMID 24562448, PMID 24827135, PMID 25596660, PMID 25963019, PMID 26094080, PMID 26183044, PMID 26540314, PMID 26818619, PMID 26911408, PMID 27733374, PMID 27865372, PMID 28284575, PMID 28592616, PMID 28945848, PMID 29259073, PMID 29370781, PMID 29413685, PMID 29501977, PMID 29769385, PMID 29855806

NIH funding

2009 (12), 2016 (5), 2008 (3), 2017 (3), 2015 (2), P30CA015083 (2), R01CA190306 (2), U10CA180820 (2), P30CA036727 (1), P30CA060553 (1), P30CA138292 (1), U10CA076001 (1)